Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HIV Clade C DNA and Protein Vaccines
NCT02915016Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2016
- Primary completion
- Aug 2019
- Modality
- Prophylactic Vaccines, Recombinant Proteins and Enzymes, DNA Vaccines
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of DNA-HIV-PT123 and bivalent subtype C gp120/MF59 in human immunodeficiency virus infection (HIV), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration and 9 more. Started Dec 2016; status: completed.
02
Drugs
DNA-HIV-PT123bivalent subtype C gp120/MF59
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02915016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02915016.